Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.

Ye S, Cohen D, Belmar NA, Choi D, Tan SS, Sho M, Akamatsu Y, Kim H, Iyer R, Cabel J, Lake M, Song D, Harlan J, Zhang C, Fang Y, Wahl AF, Culp P, Hollenbaugh D, Chao DT.

Cancer Immunol Res. 2019 Nov;7(11):1864-1875. doi: 10.1158/2326-6066.CIR-18-0805. Epub 2019 Aug 28.

PMID:
31462409
2.

CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.

Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS, Simon A, Bradley C, Thompson PA, Wahl AF, Ledbetter JA.

Clin Cancer Res. 2009 Apr 15;15(8):2739-46. doi: 10.1158/1078-0432.CCR-08-1694. Epub 2009 Apr 7.

3.

Centrifugal elutriation to obtain synchronous populations of cells.

Wahl AF, Donaldson KL.

Curr Protoc Cell Biol. 2001 May;Chapter 8:Unit 8.5. doi: 10.1002/0471143030.cb0805s02.

PMID:
18228390
4.

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.

McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I, Klussman K, Turcott E, van Rooijen N, Carter P, Grewal IS, Wahl AF, Law CL.

Blood. 2007 Feb 1;109(3):1185-92. Epub 2006 Oct 12.

PMID:
17038522
5.

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.

Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF.

Cancer Res. 2006 Feb 15;66(4):2328-37.

6.

Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.

Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law CL, Wahl AF.

J Biol Chem. 2006 Apr 14;281(15):10540-7. Epub 2006 Feb 16.

7.

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.

Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF, Senter PD.

Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.

PMID:
16417259
8.

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS.

Cancer Res. 2005 Sep 15;65(18):8331-8. Erratum in: Cancer Res. 2006 Feb 15;66(4):2495.

9.

Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.

Cerveny CG, Law CL, McCormick RS, Lenox JS, Hamblett KJ, Westendorf LE, Yamane AK, Petroziello JM, Francisco JA, Wahl AF.

Leukemia. 2005 Sep;19(9):1648-55.

PMID:
16049514
10.

In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.

Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, Senter PD, Wahl AF.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):843-52.

11.

Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.

Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, Meyer DL, Doronina SO, Siegall CB, Francisco JA, Senter PD, Wahl AF.

Clin Cancer Res. 2004 Dec 1;10(23):7842-51. Erratum in: Clin Cancer Res. 2005 May 15;11(10):3969.

12.

Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway.

Klussman K, Mixan BJ, Cerveny CG, Meyer DL, Senter PD, Wahl AF.

Bioconjug Chem. 2004 Jul-Aug;15(4):765-73.

PMID:
15264863
13.

Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD.

Nat Biotechnol. 2003 Jul;21(7):778-84. Epub 2003 Jun 1.

PMID:
12778055
14.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF.

Blood. 2003 Aug 15;102(4):1458-65. Epub 2003 Apr 24.

PMID:
12714494
15.

The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.

Wahl AF, Klussman K, Thompson JD, Chen JH, Francisco LV, Risdon G, Chace DF, Siegall CB, Francisco JA.

Cancer Res. 2002 Jul 1;62(13):3736-42.

16.

Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs.

Toki BE, Cerveny CG, Wahl AF, Senter PD.

J Org Chem. 2002 Mar 22;67(6):1866-72.

PMID:
11895404
17.

Oncostatin M in the anti-inflammatory response.

Wahl AF, Wallace PM.

Ann Rheum Dis. 2001 Nov;60 Suppl 3:iii75-80. Review.

18.

Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug.

Senter PD, Beam KS, Mixan B, Wahl AF.

Bioconjug Chem. 2001 Nov-Dec;12(6):1074-80.

PMID:
11716702
19.

Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.

Wahl AF, Donaldson KL, Mixan BJ, Trail PA, Siegall CB.

Int J Cancer. 2001 Aug 15;93(4):590-600.

20.

Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14.

Francisco JA, Donaldson KL, Chace D, Siegall CB, Wahl AF.

Cancer Res. 2000 Jun 15;60(12):3225-31.

21.

Effect of flap modifications on human FEN1 cleavage.

Bornarth CJ, Ranalli TA, Henricksen LA, Wahl AF, Bambara RA.

Biochemistry. 1999 Oct 5;38(40):13347-54.

PMID:
10529210
22.

Re-entry into the cell cycle: a mechanism for neurodegeneration in Alzheimer disease.

McShea A, Wahl AF, Smith MA.

Med Hypotheses. 1999 Jun;52(6):525-7.

PMID:
10459833
23.

Regulation of inflammatory responses by oncostatin M.

Wallace PM, MacMaster JF, Rouleau KA, Brown TJ, Loy JK, Donaldson KL, Wahl AF.

J Immunol. 1999 May 1;162(9):5547-55. Erratum in: J Immunol 2000 May 15;164(10):5531.

24.

Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease.

McShea A, Harris PL, Webster KR, Wahl AF, Smith MA.

Am J Pathol. 1997 Jun;150(6):1933-9.

25.

Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest.

Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW, Wahl AF.

J Biol Chem. 1997 May 9;272(19):12650-61.

26.
27.
28.

Activation of human monocytes through CD40 induces matrix metalloproteinases.

Malik N, Greenfield BW, Wahl AF, Kiener PA.

J Immunol. 1996 May 15;156(10):3952-60.

PMID:
8621936
29.

Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression.

Horne MC, Goolsby GL, Donaldson KL, Tran D, Neubauer M, Wahl AF.

J Biol Chem. 1996 Mar 15;271(11):6050-61.

30.

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis.

Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA.

Nat Med. 1996 Jan;2(1):72-9.

PMID:
8564846
31.

Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes.

Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D.

J Immunol. 1995 Nov 15;155(10):4917-25.

PMID:
7594496
32.
33.

Activation of p34cdc2 coincident with taxol-induced apoptosis.

Donaldson KL, Goolsby GL, Kiener PA, Wahl AF.

Cell Growth Differ. 1994 Oct;5(10):1041-50.

34.

Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle.

Donaldson KL, Goolsby GL, Wahl AF.

Int J Cancer. 1994 Jun 15;57(6):847-55.

PMID:
7911457
35.

Activity of calf thymus DNA helicase E on cis-diamminedichloroplatinum (II)-damaged DNA.

Huang L, Turchi JJ, Wahl AF, Bambara RA.

J Biol Chem. 1993 Dec 15;268(35):26731-7.

36.

Effects of the anticancer drug cis-diamminedichloroplatinum(II) on the activities of calf thymus DNA polymerase epsilon.

Huang L, Turchi JJ, Wahl AF, Bambara RA.

Biochemistry. 1993 Jan 26;32(3):841-8.

PMID:
8380711
38.

Cell cycle-dependent phosphorylation of human DNA polymerase alpha.

Nasheuer HP, Moore A, Wahl AF, Wang TS.

J Biol Chem. 1991 Apr 25;266(12):7893-903.

39.

Gene expression of human DNA polymerase alpha during cell proliferation and the cell cycle.

Wahl AF, Geis AM, Spain BH, Wong SW, Korn D, Wang TS.

Mol Cell Biol. 1988 Nov;8(11):5016-25.

40.
41.

Cell cycle dependent activities of DNA polymerases alpha and delta in Chinese hamster ovary cells.

Marraccino RL, Wahl AF, Keng PC, Lord EM, Bambara RA.

Biochemistry. 1987 Dec 1;26(24):7864-70.

PMID:
3427109
42.

Properties of two forms of DNA polymerase delta from calf thymus.

Wahl AF, Crute JJ, Sabatino RD, Bodner JB, Marraccino RL, Harwell LW, Lord EM, Bambara RA.

Biochemistry. 1986 Dec 2;25(24):7821-7.

PMID:
3099836
43.

Purification of a calf thymus DNA-dependent adenosinetriphosphatase that prefers a primer-template junction effector.

Hockensmith JW, Wahl AF, Kowalski S, Bambara RA.

Biochemistry. 1986 Dec 2;25(24):7812-21.

PMID:
3026461
44.

Purification and characterization of two new high molecular weight forms of DNA polymerase delta.

Crute JJ, Wahl AF, Bambara RA.

Biochemistry. 1986 Jan 14;25(1):26-36.

PMID:
3954990
45.

Inhibition of mammalian DNA polymerases by hematoporphyrin derivative and photoradiation.

Crute JJ, Wahl AF, Bambara RA, Murant RS, Gibson SL, Hilf R.

Cancer Res. 1986 Jan;46(1):153-9.

46.

Is Ap4A an activator of eukaryotic DNA replication?

Bambara RA, Crute JJ, Wahl AF.

Cancer Invest. 1985;3(5):473-9.

PMID:
4052834
47.

Immunoaffinity purification and properties of a high molecular weight calf thymus DNA alpha-polymerase.

Wahl AF, Kowalski SP, Harwell LW, Lord EM, Bambara RA.

Biochemistry. 1984 Apr 24;23(9):1895-9.

PMID:
6722130
48.

Alternative explanation for excision repair deficiency caused by the polAex1 mutation.

Wahl AF, Hockensmith JW, Kowalski S, Bambara RA.

J Bacteriol. 1983 Aug;155(2):922-5.

Supplemental Content

Support Center